Apellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood DisorderBenzinga • 05/17/21
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)GlobeNewsWire • 05/14/21
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual CongressGlobeNewsWire • 05/12/21
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 04/28/21
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 04/26/21
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021GlobeNewsWire • 04/21/21
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 04/16/21
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic AtrophyGlobeNewsWire • 04/13/21
Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/21
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNHGlobeNewsWire • 03/17/21
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic AtrophyGlobeNewsWire • 03/10/21
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/01/21
Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/25/21
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021GlobeNewsWire • 02/18/21